RATIO-BUPROPION SR DIN 02285665
Health Canada record
| Active ingredient(s) | BUPROPION HYDROCHLORIDE 150 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06AX12 BUPROPION |
| Original market date | 20-Nov-2006 |
| Current status date | 07-May-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BUPROPION HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02385694 | BUPROPION HCL SR | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Approved |
| 02383195 | BUPROPION HCL XL | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Approved |
| 02383187 | BUPROPION HCL XL | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Approved |
| 02561131 | BUPROPION HYDROCHLORIDE XL | YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Approved |
| 02561158 | BUPROPION HYDROCHLORIDE XL | YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Approved |
| 02275074 | ODAN BUPROPION SR | ODAN LABORATORIESLTD | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Marketed |
| 02275082 | ODAN BUPROPION SR | ODAN LABORATORIESLTD | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02565838 | ODAN-BUPROPION XL | ODAN LABORATORIESLTD | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02565846 | ODAN-BUPROPION XL | ODAN LABORATORIESLTD | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Marketed |
| 02475804 | TARO-BUPROPION XL | SUN PHARMA CANADA INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02475812 | TARO-BUPROPION XL | SUN PHARMA CANADA INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Marketed |
| 02439654 | TEVA-BUPROPION XL | TEVA CANADA LIMITED | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02439662 | TEVA-BUPROPION XL | TEVA CANADA LIMITED | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Marketed |
| 02275104 | WELLBUTRIN XL | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Marketed |
| 02275090 | WELLBUTRIN XL | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02238441 | ZYBAN | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Marketed |
| 02363399 | AVA-BUPROPION SR | AVANSTRA INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02363402 | AVA-BUPROPION SR | AVANSTRA INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02331616 | BUPROPION SR | PRO DOC LIMITEE | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02325357 | BUPROPION SR | PRO DOC LIMITEE | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02391562 | BUPROPION SR | SANIS HEALTH INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02391570 | BUPROPION SR | SANIS HEALTH INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02331829 | DOM-BUPROPION SR | DOMINION PHARMACAL | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Pre Market |
| 02317761 | DOM-BUPROPION SR | DOMINION PHARMACAL | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Pre Market |
| 02382083 | MYLAN-BUPROPION XL | MYLAN PHARMACEUTICALS ULC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 300 MG | Cancelled Post Market |
| 02382075 | MYLAN-BUPROPION XL | MYLAN PHARMACEUTICALS ULC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02299461 | NOVO-BUPROPION SR | NOVOPHARM LIMITED | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Pre Market |
| 02260239 | NOVO-BUPROPION SR TABLETS | NOVOPHARM LIMITED | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02317788 | PHL-BUPROPION SR | PHARMEL INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Pre Market |
| 02331810 | PHL-BUPROPION SR | PHARMEL INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Pre Market |
| 02313421 | PMS-BUPROPION SR | PHARMASCIENCE INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Cancelled Post Market |
| 02325373 | PMS-BUPROPION SR | PHARMASCIENCE INC | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02285657 | RATIO-BUPROPION SR | TEVA CANADA LIMITED | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02237824 | WELLBUTRIN SR | BIOVAIL PHARMACEUTICALS CANADA DIVISION OF BIOVAIL CORPORATION | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 100 MG | Cancelled Post Market |
| 02237825 | WELLBUTRIN SR | BAUSCH HEALTH, CANADA INC. | Tablet (Extended-Release) | BUPROPION HYDROCHLORIDE 150 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14210 | 2013-03-13 | Abbreviated New Drug Submission (ANDS) | Manufacturer name change |
| 8416 | 2006-11-20 | Abbreviated New Drug Submission (ANDS) | NEW MANUFACTURER AND PRODUCT NAME |
International API supply for BUPROPION HYDROCHLORIDE
27 active FDA Drug Master Files.
Request a quote for RATIO-BUPROPION SR